By the end of the year, Elan should have a clearer idea if its most prominent in-trial treatment for Alzheimer’s disease has a commercial future.

THE ISEQ index ended the week on a positive note, to close up 30.38 points to 2,629.56.

IRISH pharmaceutical company Elan is to re-balance its share offering; by making its presence on the New York Stock Exchange (NYSE) its primary listing and Dublin’s ISEQ its secondary listing.

THE head of Irish pharmaceutical company Elan received a $1 million (€725,000) bonus last year, but the Dublin and Athlone-based company still slightly decreased its total remuneration outlay to directors.

THE head of Irish pharmaceutical company Elan received a $1 million (€725,000) bonus last year, but the Dublin and Athlone-based company still slightly decreased its total remuneration outlay to directors.

IRISH pharmaceutical group Elan saw its net loss widen significantly — due to a one-off cost — last year, but also posted its first operating profit for almost a decade.

IRISH pharmaceutical group, Elan has named former Glaxo Wellcome chief executive, Robert (Bob) Ingram as its next chairman.

Drug maker Elan posted a 2% fall in revenue for the quarter ended September 30, with total revenue of $281.4m (€203.6m) for Q3 2010 down on the figure of $287m (€207m) for the same period last year.

THE Irish market performed strongly yesterday having lost ground at the end of last week.

Irish shares lost almost 1.5% of their value today, as the ISEQ index fell 45.86 points to 3,075.88 by midday today.

KELLY MARTIN is to stand down as chief executive of Elan in two years’ time, meaning that the drug company will by then have a new head and chairman in place to guide its next stage of development.

A DECISION regarding the future status of Elan’s drug-delivery business – Elan Drug Technologies (EDT) – may not be made until next year.

THE European Union has told the mother of the 25-year-old Irish man shot dead by police in Bolivia a year ago that they are willing to get involved in the search for answers regarding his death.

INTERNATIONAL healthcare giant Johnson & Johnson (J&J) formally became a significant shareholder in Irish pharmaceutical firm Elan yesterday as its amended equity investment deal was finally completed.

There were gains across the Irish Stock Exchange today in a bright day of trading.

The ISEQ index of Irish shares closed up 11.26 points to 2,876.41 today.

POSITIVE second quarter results from Elan have supported recent claims made by the company’s management that the business is on the road to recovery.

The ISEQ index of Irish shares was valued at 2,665.69 points at close of trading today, for a drop of 25.72.

The ISEQ index of Irish shares climbed 42.19 points to 2,814.55 by close of trading today.

WHILE early gains were eroded in afternoon trading, Dublin’s ISEQ share index still managed a solid enough rise — in line with the mood across Europe — as markets re-opened yesterday after the Easter holiday weekend.

SHARES in Elan — the Dublin-headquartered pharmaceutical firm — fell by nearly 5% yesterday after it announced a significant amendment to trials of its leading test treatment for Alzheimer’s disease and analysts reduced their faith in the drug making it to market.

The value of Irish shares shot up by almost 3.5% today in one of the most positive days seen on the Irish Stock Exchange for a very long time.

MARY STUTTS has been appointed by Elan as senior vice-president and head of corporate relations — a newly created post at the Irish-American drug-making company.

Shy bartender Jean works in a luxury hotel in Biarritz as a dog walker. Among the guests is money-grabbing Irene and her latest sugar daddy, Jacques, who has the gall to fall asleep during her birthday.

The Irish Stock Exchange rebounded today, with the ISEQ index climbing 120.72 points to 3,943.66.

The value of Irish shares slumped by almost 4% today in another day of turmoil on the Irish Stock Exchange.

The Irish Stock Exchange took another heavy hit this morning after yesterday’s disastrous losses, as the value of Irish shares dived by more than 2%.

ELAN and Wyeth have suspended a study on a vaccine targeted at a suspected cause of Alzheimer’s disease, according to the website ClinicalTrials.gov.

The ISEQ index finished down 31.75 points to 6,205.31 today.

Today saw some positive trading on the Irish Stock Exchange, with the ISEQ index closing up 37.44 points to 6,389.40.

ELAN’s up and down year has turned positive with US drug giant, Wyeth — which partners Elan on its in-development Alzheimer’s treatments — saying drugs they are working on “may have a higher likelihood of succeeding than anybody’s”.

ELAN was given an “outperform” rating by Credit Suisse and added to the bank’s “Focus List” on optimism about sales of the Tysabri multiple sclerosis medicine and an Alzheimer’s drug.

Elan Corporation, plc today announced its full-year and fourth quarter 2007 financial results and provided guidance for its financial outlook for 2008.

ELAN said yesterday that it is fully committed to its multiple sclerosis treatment Tysabri after its production partner — the US-based company Biogen Idec — announced it was not about to be taken over and would remain independent.

The value of Irish shares increased by more than one and a quarter percentage points after an optimistic day’s trading on the Irish Stock Exchange today.

The Irish Stock Exchange rallied from some poor morning of trading to climb to 8222.73 points by 11:46am today, a rise of 27.14 points from close of business yesterday.

Elan have announced that Dr Lars Ekman, currently president of Research and Development, member of the Operating Committee and the Board of Directors, will transition from his current operational role to become an advisor as a member of the Board of Directors.

FIELDS, the Dublin-based jewellers, is expanding into the British market with the takeover of the 31-store Fraser Hart Group.

The ISEQ index was down 31.24 point 8997.39 to by 11.30am in a busy morning for the Irish Stock Exchange.

Predictions of another interest rate increase from the European Central Bank worsened the crisis of confidence in the Irish Stock Exchange.

Athlone-based pharmaceutical company Elan and Wyeth Pharmaceuticals are to initiate a phase three clinical programme of a drug for the treatment of patients with mild to moderate Alzheimer's Disease.

Elan Corporation today announced a number of changes to its board of directors.

The ISEQ index of Irish shares continued in buoyant form this morning, once again breaking through the 10,000 barrier, rising up 36.72 points to 10017.8 by 11.25am.

Elan Corporation, plc today announced its full-year and fourth quarter 2006 financial results and provided guidance for its financial outlook for 2007.